GPC2 antibody-drug conjugate could change the tumor microenvironment (TME) to a proinflammatory state in neuroblastoma, and might promote immunogenic cell death and enhance antitumor immune response(.Pascual-Pasto et al. 2022). This evidence concerns the gene GPC2 and neuroblastoma.